Medtronic plc (NYSE:MDT) is listed among the Top 15 Growth Stocks for Long-Term Investors. The company’s focus on R&D and emerging markets drives its dividend success. With operations in Cardiovascular, Neuroscience, Medical Surgical, and Diabetes segments, revenue from emerging markets is growing at a double-digit pace, outpacing US growth.

Revenue from emerging markets has been growing at a double-digit pace, outpacing US growth. Medtronic plc (NYSE:MDT) has completed nine acquisitions since 2021, totaling over $3.3 billion, to expand its capabilities. The company’s annual R&D spending exceeds $2 billion, driving continuous product innovation and maintaining its leadership in the medical technology space.

Medtronic plc (NYSE:MDT) continues to draw investor interest with its dividend growth. The company has increased its dividend for 48 consecutive years, offering a quarterly dividend of $0.71 per share with a dividend yield of 2.98%. While MDT shows investment potential, other AI stocks may offer greater upside and less downside risk.

For more promising dividend stocks, check out the 12 Most Promising Dividend Stocks According to Wall Street Analysts and the 14 Best Food Dividend Stocks To Buy According to Analysts. No disclosures.

Read more at Yahoo Finance: How Medtronic’s (MDT) R&D and Emerging Market Strategy Drive its Dividend Success